Atossa Therapeutics (ATOS)

Executive Summary

Atossa Therapeutics is a clinical-stage biopharmaceutical company developing (Z)-endoxifen, a potent selective estrogen receptor modulator (SERM), for the treatment and prevention of breast cancer. The company is advancing its lead asset across the breast cancer continuum, including a Phase 2 trial for breast density reduction (NCT05068388) that completed in December 2025, and a Phase 2 study in estrogen receptor-positive/HER2-negative invasive breast cancer (NCT05607004) that is actively recruiting. (Z)-endoxifen aims to provide a more effective and tolerable alternative to existing SERMs like tamoxifen. Atossa's pipeline also includes earlier-stage programs, but the company's near-term value is driven by the potential of endoxifen to address significant unmet needs in breast cancer prevention and treatment. With a lean operation and a focused strategy, Atossa is positioned to deliver meaningful clinical data in the coming quarters.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 breast density trial topline results70% success
• Q4 2026Initiation of Phase 3 program for breast density or prevention50% success
• Q3 2026FDA meeting or guidance on endoxifen development pathway60% success